Research ExplorerPublicationsThe ACCOST-HH Trial

The ACCOST-HH Trial

Standard

The ACCOST-HH Trial : An investigator-initiated trial, the placebo-controlled, double-blind, multi-centre, randomized trial to assess the efficacy and safety of the antibody AdreCizumab (HAM8101) against plaCebO in SubjecTs witH cardiogenic sHock, (ACCOST-HH) in progress is discussed. / Skurk, Carsten; Rottbauer, Wolfgang; Kessler, Mirjam; Akin, Ibrahim; Kluge, Stefan; Burdelski, Christoph; Blankenberg, Stefan; Zeller, Tanja; Landmesser, Ulf; Karakas, Mahir.

In: EUR HEART J, Vol. 41, No. 45, 01.12.2020, p. 4296-4298.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Skurk, C, Rottbauer, W, Kessler, M, Akin, I, Kluge, S, Burdelski, C, Blankenberg, S, Zeller, T, Landmesser, U & Karakas, M 2020, 'The ACCOST-HH Trial: An investigator-initiated trial, the placebo-controlled, double-blind, multi-centre, randomized trial to assess the efficacy and safety of the antibody AdreCizumab (HAM8101) against plaCebO in SubjecTs witH cardiogenic sHock, (ACCOST-HH) in progress is discussed', EUR HEART J, vol. 41, no. 45, pp. 4296-4298. https://doi.org/10.1093/eurheartj/ehaa757

APA

Skurk, C., Rottbauer, W., Kessler, M., Akin, I., Kluge, S., Burdelski, C., Blankenberg, S., Zeller, T., Landmesser, U., & Karakas, M. (2020). The ACCOST-HH Trial: An investigator-initiated trial, the placebo-controlled, double-blind, multi-centre, randomized trial to assess the efficacy and safety of the antibody AdreCizumab (HAM8101) against plaCebO in SubjecTs witH cardiogenic sHock, (ACCOST-HH) in progress is discussed. EUR HEART J, 41(45), 4296-4298. https://doi.org/10.1093/eurheartj/ehaa757

Vancouver

Skurk C, Rottbauer W, Kessler M, Akin I, Kluge S, Burdelski C et al. The ACCOST-HH Trial: An investigator-initiated trial, the placebo-controlled, double-blind, multi-centre, randomized trial to assess the efficacy and safety of the antibody AdreCizumab (HAM8101) against plaCebO in SubjecTs witH cardiogenic sHock, (ACCOST-HH) in progress is discussed. EUR HEART J. 2020 Dec 1;41(45):4296-4298. https://doi.org/10.1093/eurheartj/ehaa757

Bibtex

@article{dafa5820e4be42ebbb4a54d86590631e,
title = "The ACCOST-HH Trial: An investigator-initiated trial, the placebo-controlled, double-blind, multi-centre, randomized trial to assess the efficacy and safety of the antibody AdreCizumab (HAM8101) against plaCebO in SubjecTs witH cardiogenic sHock, (ACCOST-HH) in progress is discussed",
author = "Carsten Skurk and Wolfgang Rottbauer and Mirjam Kessler and Ibrahim Akin and Stefan Kluge and Christoph Burdelski and Stefan Blankenberg and Tanja Zeller and Ulf Landmesser and Mahir Karakas",
year = "2020",
month = dec,
day = "1",
doi = "10.1093/eurheartj/ehaa757",
language = "English",
volume = "41",
pages = "4296--4298",
journal = "EUR HEART J",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "45",

}

RIS

TY - JOUR

T1 - The ACCOST-HH Trial

T2 - An investigator-initiated trial, the placebo-controlled, double-blind, multi-centre, randomized trial to assess the efficacy and safety of the antibody AdreCizumab (HAM8101) against plaCebO in SubjecTs witH cardiogenic sHock, (ACCOST-HH) in progress is discussed

AU - Skurk, Carsten

AU - Rottbauer, Wolfgang

AU - Kessler, Mirjam

AU - Akin, Ibrahim

AU - Kluge, Stefan

AU - Burdelski, Christoph

AU - Blankenberg, Stefan

AU - Zeller, Tanja

AU - Landmesser, Ulf

AU - Karakas, Mahir

PY - 2020/12/1

Y1 - 2020/12/1

U2 - 10.1093/eurheartj/ehaa757

DO - 10.1093/eurheartj/ehaa757

M3 - SCORING: Journal article

C2 - 33111142

VL - 41

SP - 4296

EP - 4298

JO - EUR HEART J

JF - EUR HEART J

SN - 0195-668X

IS - 45

ER -